Suppr超能文献

β肾上腺素受体阻滞剂在心房颤动中的应用:部分激动剂活性的重要性

Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity.

作者信息

Channer K S, James M A, MacConnell T, Rees J R

机构信息

Department of Cardiology, Bristol Royal Infirmary.

出版信息

Br J Clin Pharmacol. 1994 Jan;37(1):53-7. doi: 10.1111/j.1365-2125.1994.tb04238.x.

Abstract
  1. The ideal drug treatment for atrial fibrillation will control resting heart rate, blunt exercise induced tachycardia whilst not exacerbating nocturnal bradycardia. Monotherapy with digoxin may not be ideal. We have compared the effect of combining digoxin (0.25 mg daily) with atenolol 50 mg and 100 mg or pindolol 5 mg twice daily and 15 mg twice daily in a cross-over randomised single-blind trial in eight symptomatic patients (six male; mean age 62 years) with poorly controlled atrial fibrillation. 2. Heart rate control was measured by 24 h ECG at baseline on digoxin therapy and after 2 weeks with each treatment. Symptom scores for breathlessness and palpitation were measured using visual analogue scales. 3. The addition of both beta-adrenoceptor blockers significantly reduced mean diurnal maximum heart rate from baseline (all P < 0.001 ANOVA). Atenolol at both doses caused a greater reduction than either dose of pindolol (P < 0.001 ANOVA). Nocturnal maximum heart rate was not significantly reduced from baseline by either beta-adrenoceptor blocker, but both doses of pindolol caused increases in nocturnal maximum heart rate compared with atenolol (P < 0.001 ANOVA). 4. Atenolol caused a reduction in diurnal minimum heart rate compared with baseline and caused a reduction in nocturnal minimum heart rate whereas pindolol caused an increase (P < 0.001 ANOVA). 5. Atenolol 100 mg caused longer nocturnal pauses compared with baseline but pindolol 15 mg twice daily reduced the number of nocturnal pauses > 1.5 s (P = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
摘要
  1. 理想的房颤药物治疗应能控制静息心率,抑制运动诱发的心动过速,同时不加重夜间心动过缓。单用洋地黄可能并非理想选择。我们在一项交叉随机单盲试验中,比较了洋地黄(每日0.25毫克)联合阿替洛尔50毫克和100毫克或吲哚洛尔每日两次5毫克和15毫克对8例症状性房颤患者(6例男性;平均年龄62岁)的疗效,这些患者的房颤控制不佳。2. 通过24小时心电图在洋地黄治疗基线时及每种治疗2周后测量心率控制情况。使用视觉模拟量表测量呼吸困难和心悸的症状评分。3. 两种β受体阻滞剂的添加均使平均日间最大心率较基线显著降低(方差分析均P<0.001)。阿替洛尔的两种剂量所致降低幅度均大于吲哚洛尔的任一剂量(方差分析P<0.001)。两种β受体阻滞剂均未使夜间最大心率较基线显著降低,但与阿替洛尔相比,吲哚洛尔的两种剂量均使夜间最大心率增加(方差分析P<0.001)。4. 与基线相比,阿替洛尔使日间最低心率降低,且使夜间最低心率降低,而吲哚洛尔则使其升高(方差分析P<0.001)。5. 与基线相比,阿替洛尔100毫克使夜间停搏时间延长,但吲哚洛尔每日两次15毫克减少了夜间停搏时间>1.5秒的次数(P=0.05)。(摘要截断于250字)

相似文献

引用本文的文献

5
Current management of symptomatic atrial fibrillation.症状性心房颤动的当前管理
Drugs. 2001;61(10):1425-37. doi: 10.2165/00003495-200161100-00006.

本文引用的文献

4
Towards improved control of atrial fibrillation.迈向改善心房颤动的控制
Eur Heart J. 1987 Feb;8(2):141-7. doi: 10.1093/oxfordjournals.eurheartj.a062241.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验